Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galaxy MedicareNSE:GML +0.84%19 EV-to-EBIT is 3.67 as of Aug. 12, 2026, which is 39% below its 10-year median of 6.06. GuruFocus rates NSE:GML with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 472 Medical Devices & Instruments companies, Galaxy Medicare ranks better than 94.49% on this metric.
The historical rank and industry rank for Galaxy Medicare's EV-to-EBIT or its related term are showing as below:
NSE:GML'
s EV-to-EBIT Range Over the Past 10 Years
Min: 3.28 Med: 6.06 Max: 14.5
Current: 3.67
During the past 5 years, the highest EV-to-EBIT of Galaxy Medicare was 14.50. The lowest was 3.28. And the median was 6.06.
NSE:GML's EV-to-EBIT is ranked better than 94.49% of 472
companies
in the Medical Devices & Instruments industry
Industry Median: 19.215
vs NSE:GML: 3.67
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Galaxy Medicare's Enterprise Value for the quarter that ended in Mar. 2026 was ₹159.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galaxy Medicare's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹49.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galaxy Medicare EV-to-EBIT Related Terms
Galaxy Medicare EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Galaxy Medicare's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Galaxy Medicare's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galaxy Medicare EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Galaxy Medicare's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Galaxy Medicare's EV-to-EBIT falls into.
Galaxy Medicare's current Enterprise Value is ₹182.7 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Galaxy Medicare's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹49.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galaxy Medicare (NSE:GML) has a EV-to-EBIT of 3.67 as of Aug. 12, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Galaxy Medicare and its competitors. This is 39% below median its historical median of 6.06. Over the past decade, Galaxy Medicare's EV-to-EBIT has ranged from 3.28 to 14.50. According to the industry distribution chart, Galaxy Medicare ranks #26 out of 472 companies in the Medical Devices & Instruments industry, placing it in the top 5.5%.
Is Galaxy Medicare's EV-to-EBIT too high?
Galaxy Medicare's current EV-to-EBIT of 3.67 is 39% below median its 10-year median of 6.06. Over the past 10 years, this metric has ranged from a low of 3.28 to a high of 14.50. The Medical Devices & Instruments industry median EV-to-EBIT is 19.22. Galaxy Medicare's value of 3.67 is 80.9% below this industry median. Based on the distribution chart, Galaxy Medicare ranks #26 out of 472 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Galaxy Medicare has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Galaxy Medicare's EV-to-EBIT compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Galaxy Medicare ranks #26 out of 472 companies for EV-to-EBIT. This places Galaxy Medicare in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 19.22. Galaxy Medicare's value of 3.67 is 80.9% below this benchmark. Historically, Galaxy Medicare's own EV-to-EBIT has ranged from 3.28 to 14.50 over the past decade. While the company's 10-year median is 6.06 vs. the industry median of 19.22, Galaxy Medicare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 19.22, based on 472 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galaxy Medicare's current EV-to-EBIT of 3.67 is 80.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Galaxy Medicare and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 19.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galaxy Medicare's current EV-to-EBIT is 3.67, which is 39% below median its own 10-year median of 6.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galaxy Medicare stock overvalued right now?
Galaxy Medicare (NSE:GML) has a current EV-to-EBIT of 3.67. The current EV-to-EBIT is 3.67, which is 39% below median its 10-year median of 6.06 and 80.9% below the Medical Devices & Instruments industry median of 19.22. Galaxy Medicare's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Galaxy Medicare (NSE:GML), the current EV-to-EBIT is 3.67 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galaxy Medicare Ltd is engaged into the manufacturing, trading and exporting of Medical Devices, Plasters of Paris Bandages (POP Bandage) and Other surgical dressings in India. Its business encompass: Manufacturing and Branding of its own products under its flagship brands i.e. POP BAND, POP CAST, G CAST, GYPSOSOFT, GYPSOPLAST, CARETAPE, GYPSOCREPE, CARECREPE, CAREPORE GYPSONET, GYPSOCHLOR, FIXCAN ETC.
19GF Score
Get the complete analysis for NSE:GML
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:GML has been successfully added to your 
